References
- Nishimura K, Wakimoto N, Sasahara J, Yanagisawa C, Eda F, Nishino J, et al. No change of infliximab levels in stored blood for preoperative autologous blood donation: a preliminary report. Mod Rheumatol. 2005;15:302–4.
- Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552–63.
- Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs. 2000;59:1341–59.
- Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe S, Probert L, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine. 1995;7:15–25.
- Maini RN, Elliott MJ, Long-Fox A, Feldmann M, Kalden JR, Antonio C, et al. Clinical response of rheumatoid arthritis (RA) to anti-TNF alpha (cA2) monoclonal antibody (mab) is related to administered dose and persistence of circulating antibody [abstract]. Arthritis Rheum. 1995;38 Suppl:5186.
- Hanauer SB. Safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999;13 Suppl 4:16–22.
- Maini R, Clair EWS, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant mathotrexate: a randomised phase III trial. Lancet. 1999;354:1932–9.
- Lipsky PE, van der Heijde DMFM, Clair WS, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;30:1594–602.
- Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman frill, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051–65.
- Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbiditied. A large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54:1075–86.
- Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int. 2004;25:331–5.
- Wendfing D, Balblanc J-C, Brousse A, Lohse A, Lehuede G, Garbuio P, et al. Surgery in patients receiving anti-tumor necrosis factor a treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis. 2005;64: 1378–9.
- den Broeder AA, Creemers MCW, Fransen J, de Jong E, de Rooji DR, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti tumor necrosis factor: a large retrospective study. J Rheumatol. 2007;34:689–95.
- Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Raffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arhtritis. Arthritis Care Res. 2006;55:333–7.
- Ledingham J, Deighton C. Update on the British society for rheumatology guidelines for prescribing TNFa blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology. 2005;44:157–63.
- Mochizuki T, Momohara S, Ikari K, Okamoto H, Kobayashi S, Tsukahara S, et al. The serum concentration of infliximab in cases of autologous blood donation for patients with rheumatoid arthritis. Mod Rheumatol. 2007;17:24–7.
- Fujiwara T. Precfinical and clinical investigations of infliximab (Remicadeg), a novel human/murine chimeric monoclonal anti-body preparation raised against human TNFa (in Japanese). Jpn Pharmacol Ther. 2005;33:581–626.